Statement of Changes in Beneficial Ownership (4)
March 03 2020 - 4:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Nanavaty Maulik |
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP
[
BSX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP & Pres, Neuromodulation |
(Last)
(First)
(Middle)
300 BOSTON SCIENTIFIC WAY |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/28/2020 |
(Street)
MARLBOROUGH, MA 01752-1234
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/28/2020 | | M | | 1629.0000 | A | $0.0000 (1) | 267539.0000 (2) | D | |
Common Stock | 2/28/2020 | | F | | 808.0000 | D | $37.3900 | 266731.0000 (2) | D | |
Common Stock | 3/2/2020 | | M(3) | | 9623.0000 | A | $16.3100 | 276354.0000 (2) | D | |
Common Stock | 3/2/2020 | | S(3) | | 16763.0000 | D | $37.4744 (4) | 259591.0000 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Deferred Stock Units | (1) | 2/28/2020 | | M | | | 1629.0000 | (5) | 2/28/2022 (5) | Common Stock | 1629.0000 | $0.0000 | 3259.0000 | D | |
Stock Option (Right to Buy) | $16.3100 | 3/2/2020 | | M (3) | | | 9623.0000 | (6) | 2/23/2025 | Common Stock | 9623.0000 | $0.0000 | 0.0000 | D | |
Explanation of Responses: |
(1) | Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
(2) | Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. |
(3) | This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. |
(4) | Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.35 to $37.655, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
(5) | Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
(6) | Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Nanavaty Maulik 300 BOSTON SCIENTIFIC WAY MARLBOROUGH, MA 01752-1234 |
|
| SVP & Pres, Neuromodulation |
|
Signatures
|
/s/ Scott G. Hodgdon, Attorney-in-Fact | | 3/3/2020 |
**Signature of Reporting Person | Date |
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Sep 2023 to Sep 2024